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The objective is to provide an update on the clinical efficacy, safety and tolerability of the use of abatacept 
for treating rheumatoid arthritis. A systematic review (up to June 2011) followed by meta-analyses 
was performed. Randomized controlled clinical trials comparing abatacept at a dose of 10 mg/kg with 
a placebo, both with concomitant methotrexate, were used. Only high- or moderate-quality studies 
were included. The efficacy was evaluated based on changes in the ACR, DAS and HAQ; safety was 
assessed based on serious adverse events, serious infections, malignancies and deaths; tolerability was 
evaluated based on the withdrawals due to adverse events, serious adverse events and lack of efficacy. 
All these parameters were evaluated within one year of treatment. Nine studies met the inclusion criteria, 
comprising 4,219 patients. For all of the efficacy parameters, the abatacept group had better results than the 
placebo group, except in the case of HAQ improvement >0.3, which presented no statistically significant 
difference. None of the safety parameters presented a significant difference between the groups. The 
tolerability parameters were also similar between groups, with the exception of withdrawals due to lack 
of efficacy. For this criterion, the abatacept group presented favorably compared to the control group. 
Abatacept showed a higher efficacy compared to placebo without significant differences between the 
abatacept and control group in terms of safety.
Uniterms: Abatacept/efficacy. Rheumatoid arthritis/treatment. Meta-analyses.
O objetivo foi fornecer dados atualizados sobre eficácia clínica, segurança e tolerabilidade do uso de 
abatacepte para o tratamento da artrite reumatoide. Realizaram-se uma revisão sistemática (com dados 
até junho/2011) e metanálises. Somente estudos clínicos controlados randomizados comparando o 
abatacepte (10 mg/kg) com placebo, ambos com uso concomitante de metotrexato, foram incluídos; 
todos possuíam qualidade alta ou moderada. A eficácia foi avaliada baseando-se em mudanças no ACR, 
DAS e HAQ; a segurança foi avaliada pelos eventos adversos e infecções graves, malignidades e mortes 
e a tolerabilidade pelo abandono do tratamento devido a eventos adversos (graves ou não) e falta de 
eficácia. Todos esses parâmetros foram avaliados ao final de um ano de tratamento. Nove estudos se 
adequaram aos critérios de inclusão, envolvendo 4219 pacientes. Em todos os parâmetros avaliados, o 
grupo tratado com abatacepte obteve melhores resultados, exceto para a melhora (>0,3) no HAQ (sem 
diferença estatisticamente significativa). Nenhum critério de segurança ou tolerabilidade apresentou 
diferença significativa entre os grupos, com exceção dos abandonos devido à falta de eficácia (grupo 
abatacepte apresentou resultados favoráveis em relação ao controle). O abatacepte possui maior eficácia 
quando comparado com o placebo, sem diferença significativa entre os grupos em termos de segurança.
Unitermos: Abatacepte/eficácia. Artrite reumatóide. Metanálise.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune 
disease with a worldwide prevalence of approximately 
1%. The disease leads to joint inflammation and destruc-
tion and generates a decrease in the health-related quality 
of life, functional limitations and work disability, mainly 
due to pain and fatigue (Bagust et al., 2009; Singh et al., 
2009; Cortejoso-Fernandez et al., 2012).
Cytokines, interleukins-1b and 6 (IL-1b and 6) and 
tumor necrosis factor (TNF) are known to play important 
roles in joint destruction in RA. The activation of T and B 
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cells leads to a cascade of events, including the release of 
cytokines that are responsible for inflammation and joint 
destruction. Abatacept (ABT) modulates the stimulation of 
T cells, which subsequently control the function of B cells, 
macrophages and osteoclasts and the release of cytokines, 
matrix metalloproteinases and antibodies (Bruce, 2009; 
Falgarone et al., 2009). ABT is a fusion protein made up 
of the Fc portion of human immunoglobulin and cytotoxic 
T-lymphocyte associated antigen 4. ABT blocks the cas-
cade of activation of T cells (Smolen et al., 2007; Bruce, 
2009; Mola et al., 2012).
ABT was shown to be safe and efficient for patients 
with an inadequate response to TNF antagonists and 
methotrexate (MTX) in some randomized controlled clini-
cal trials (RCT). Treatment with ABT resulted in decreases 
in arthritis, pain, disability, fatigue and radiological joint 
damage, and the efficacy was maintained over time (Geno-
vese et al., 2005; Kremer et al., 2005; Kremer et al., 2006; 
Genant et al., 2008; Schiff et al., 2008; Falgarone et al., 
2009; Rubbert-Roth; Finckh, 2009; Russell et al., 2009; 
Russell et al., 2009; Mola et al., 2012).
Although RTC have shown the effectiveness of ABT 
in treating the signs and symptoms of AR, indiscriminate 
use must be avoided and continued evaluations must be 
conducted due to the lack of information about the long-
term safety (Cortejoso-Fernández et al., 2012). According 
to a review by Cochrane, ABT presents a better safety 
profile than most other biologics (Malaviya, Östör, 2012). 
This study provides a systematic review and meta-analyses 
to evaluate the efficacy, safety and tolerability of ABT 
pharmacotherapy for RA interventions based on updated 
evidence, including systematic reviews and meta-analyses.
METHODS
A systematic review and meta-analyses were per-
formed of RCT that compared the use of ABT at a dose of 10 
mg/kg versus placebo, both with concomitant MTX. In the 
included studies, ABT was given endovenously at days 1, 15 
and 29 and every 4 weeks thereafter. Only studies involving 
adult patients with active RA (as defined by the American 
College of Rheumatology - ACR - criteria) and with mod-
erate to high quality were included (according to Jadad’s 
Scale) (Jadad et al., 1996). Other inclusion criteria were as 
follows: studies that reported clinical outcomes and were 
available as full-text publications. Interventional studies 
were excluded if they were not randomized or double-blind.
Two independent reviewers performed the system-
atic review and applied Jadad’s Scale (Jadad et al., 1996) 
for quality evaluation of the studies. The two reviewers 
extracted the data from the articles in pre-defined tables. 
In the case of a difference between the data extracted by 
the reviewers, the discordant data were discussed and 
consensual values were adopted.
The electronic databases used in the systematic 
review were as follows: Medline, Embase, Chocrane 
Library, Scielo, Lilacs and International Pharmaceutical 
Abstracts. The search was performed for relevant studies 
up to June 2011. Language and date of study publication 
were not exclusion criteria. As descriptors, the following 
expressions were used: rheumatoid arthritis AND abata-
cept. No search filters were used for the type of study 
restriction, except for in Medline (in which we only looked 
for clinical trials, meta-analyses, RCT, and clinical trials) 
and IPA (in which we only searched for original articles).
The clinical outcomes adopted for the evaluation 
of treatment were the following: the response of RA to 
treatment with ABT according to the ACR criteria (ACR 
20, 50 and 70); a Disease Activity Score in 28 joints indi-
cating the remission of the pathology (DAS28≤2.6) and 
a low disease activity (DAS28≤3.2); and HAQ variation 
and improvement (DHAQ≥0.3). Additionally, the safety 
outcomes considered were as follows: serious adverse 
events (SAE), serious infections (SI), malignancies and 
deaths. For the tolerability evaluation, withdrawals due to 
adverse events, SAE or lack of efficacy were measured. 
All parameters were evaluated after one year of treatment, 
according to the available data in the included studies.
For statistical analyses, the software Review 
Manager 5.0, from Cochrane Collaboration, was used. 
Dichotomous variables were evaluated using the risk 
ratio with the inverse variance model, with a confidence 
interval of 95% (random effect model). HAQ variation 
was the only continuous variable, and it was evaluated by 
the mean difference and inverse variance model, with the 
same confidence interval. The random effect model was 
chosen due to the high heterogeneity in the data that could 
not be explained.
Statistical heterogeneity among the results was as-
sessed using I2, a common metric method for measuring 
the magnitude of this variable. The interpretation of I2 is 
relatively simple: its value varies from 0% to 100%, and 
in situations where I2<25%, the statistical heterogeneity 
is considered low; it is considered moderate and high for 
values between 25% and 50% and for values above 50%, 
respectively (Hakkinen et al., 2006; Huedo-Medina et 
al., 2006).
A sensitivity analysis was also performed in this 
study. The method adopted for evaluating the robustness 
of the study was as follows: the data were reviewed with 
exclusion of data of studies or groups of studies. The data 
were also reviewed using different statistical methods.
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RESULTS
In the systematic review, 42 potentially relevant 
articles were identified, of which 29 were excluded on the 
basis of the title or abstract. The remaining 13 articles were 
evaluated by two independent reviewers, and 4 studies 
were excluded upon reading the full text. The remaining 9 
articles were included in the meta-analyses based on their 
quality and their accordance with the inclusion criteria. 
Figure 1 is a scheme of the systematic review, and Table 
I shows the main characteristics of the excluded studies 
and the reasons for their exclusion.
Description of the included studies
Twelve studies met the inclusion criteria and were 
included in the meta-analyses. All of the included studies 
were sponsored by Bristol-Myers Squibb. A chronologi-
cal summary of the baseline characteristics of the patients 
involved in the included studies is shown in Table II.
The mean age of the patients across all trials ranged 
from 49.1 to 54.6 years. The gender distribution was also 
similar across trials (all trials had a 3:1 ratio of females to 
males). Both the mean age and gender distribution values 
are consistent with the epidemiology of RA [1, 2]. The 
data for the mean number of swollen and tender joints 
were also similar across the studies; however, the mean 
disease duration was heterogeneous across the studies 
(ranged from 3.4 to 12.9 years).
FIGURE 1 - Results of the systematic review. RCT – Randomized 
controlled trial.
TABLE I - Characteristics of the excluded studies
REFERENCE REASON FOR EXCLUSION
Alten, 2006
Chung, 2006
Genant, 2008
Genovese, 2008
Kremer, 2008
Maxwell, 2009
Ostor, 2008
Russell, 2009
Schiff, 2009
Singh, 2009
Singh, 2009
Vera-Llonch, 2008
Venkateshan, 2009
Westhovens, 2009
Not a randomized controlled clinical trial
Dougados, 2009 Without a control group
Hasset, 2008
Analyzed data from another study 
(Genovese et al., 2005)
Li, 2008
Moreland, 2002
Involved an intervention that was not 
relevant for this meta-analyses
Ma, 2009 Pharmacokinetic study
Cole, 2008
Emery, 2006
Marti, 2009
Martin, 2007
Russel, 2007
Weisman, 2006
Wells, 2008
Westhovens, 2006
Compared outcomes that were not of 
interest for the meta-analyses
Ruperto, 2008 Abatacept was prescribed for juvenile rheumatoid arthritis
Salliot, 2009 Adverse events meta-analysis
Meta-analyses results for efficacy
For evaluation of the efficacy of ABT, the following 
data were extracted from the studies: the proportion of pa-
tients who achieved ACR20, ACR50, ACR70, DAS28≤3.2 
and DAS28≤2.6; the mean HAQ variation from baseline 
to the end of the follow-up; and the proportion of patients 
who showed an improvement of 0.3 or more in the HAQ 
scale. All the parameters were measured after one year of 
continuous treatment.
Considering the ACR outcomes, four studies pro-
vided data of the outcomes within one year of treatment 
(Kremer et al., 2005; Kremer et al., 2006; Schiff et al., 
2008; Westhovens et al., 2009a). In two other studies, 
the interventions included concomitant anti-TNF agent 
(Genovese et al., 2005; Weinblatt et al., 2007). The articles 
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used in the meta-analyses involved the following interven-
tion: ABT 10mg/kg+MTX versus placebo+MTX. 
The Risk Ratios (RR) comparing ABT versus the 
control groups were as follows: 1.60 [1.28, 2.01] for 
ACR20, 1.98 [1.35, 2.91] for ACR50 and 2.47 [1.51, 
4.03] for ACR70 (Figure 2). In total, 71% of the patients 
achieved ACR20 after one year of treatment with ABT 
compared to 43% of the control group. For ACR50 and 
ACR70, the values were 49% and 37% for the ABT group 
and 28% and 16% for the control group, respectively.
High statistical heterogeneities among the studies 
(I2>50%) were observed for the three outcomes (ACR20, 
50 and 70). No clinical or methodological differences 
among the studies were observed to be able to cause these 
heterogeneities.
The proportions of patients with low disease activity 
and who experienced remission were also evaluated in our 
meta-analyses using DAS28. The RR values comparing the 
ABT and control groups were 3.09 [1.68, 5.68] and 3.88 
[1.48, 10.16] for the percentages of patients who achieved 
DAS28≤3.2 (low disease activity) and DAS28≤2.6 (disease 
remission), respectively, within one year of treatment. In 
total, 44% of patients achieved values of DAS28≤3.2 in 
the ABT group; in the control group, this value was 14%. 
A total of 31% of the patients in the ABT group presented 
remission of the disease according to the DAS28 criteria; 
for the control group, this value was 13% (Figure 3).
The statistical heterogeneity was high for both of the 
DAS28 outcomes. No clinical or methodological differ-
ences in the studies could account for this heterogeneity.
The meta-analysis of the variation of the HAQ from 
baseline to the end of follow-up involved only two stud-
TABLE II - Patients’ baseline characteristics in the included studies
Study (Jadad Score) 
Intervention
Number of 
patients
Mean age 
(years)
Mean disease 
duration 
(years)
Mean number 
of swollen 
joints
Mean number 
of tender 
joints
% of 
patients on 
DMARD
Mean 
HAQ 
score
Moreland, 2002 (4)
ABT 10mg/kg + MTX
Placebo + MTX
64 51.5 3.4 23.3 29.5 N.A. N.A.
Kremer, 2003 (4)
ABT 10mg/kg + MTX
Placebo + MTX
234 54.6 9.3 21.1 28.7 N.A. 1.0
Genovese, 2005* (5)
ABT 10mg/kg + MTX
Placebo + MTX
391 53.2 11.9 22.2 31.7 N.A. 1.8
Kremer, 2005 (4)
ABT 10mg/kg + MTX
Placebo + MTX
234 54.6 9.3 21.1 28.7 N.A. N.A.
Kremer, 2006 (4)
ABT 10mg/kg + MTX
Placebo + MTX
652 51.1 8.6 21.6 31.4 11.0 1.7
Weinblatt, 2006 (5)
ABT 10mg/kg + DMARD
Placebo + DMARD
1274 52.1 9.5 19.8 28.9 89.8 1.5
Weinblatt, 2007 (4)
ABT 10mg/kg + ETA
Placebo + ETA
121 51.1 12.9 19.7 28.8 N.A. N.A.
Schiff, 2008 (5)
ABT 10mg/kg + MTX
Placebo + MTX
266 49.1 8.1 20.8 31.1 N.A. 1.8
Westhovens, 2009 (4)
ABT 10mg/kg + MTX
Placebo + MTX
509 49.9 6.4 22.4 31.1 3.3 1.7
*Intervention with or without concomitant anti-TNF; DMARD: disease-modifying antirheumatic drugs; HAQ: health assessment 
questionnaire; N.A.: not available; ABT: abatacept; MTX: methotrexate; ETA: etanercept
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FIGURE 2 - Meta-analysis of ACR20 (top), ACR50 (middle) and ACR70 (bottom). ABT – abatacept; MTX – methotrexate. IV – 
inverse variance; CI – confidence interval.
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FIGURE 3 - Meta-analysis of low disease activity (DAS≤3.2) and disease remission (DAS≤2.6) – top and bottom, respectively. 
ABT – abatacept; MTX – methotrexate. IV – inverse variance; CI – confidence interval.
ies (Kremer et al., 2006; Westhovens et al., 2009a), both 
of which had ABT + MTX versus placebo+MTX as the 
intervention. The values included in the meta-analysis 
resulted in a mean difference of 0.19 [0.20, 0.19], favoring 
the ABT group. A high heterogeneity was also observed 
in this parameter, which could not be explained by the 
methodologies of the included studies (Figure 4).
For HAQ improvement ≥ 0.3, two studies were 
included in the meta-analysis (Kremer et al., 2006; 
Westhovens et al., 2009a). The result was an RR value of 
1.36 [0.98, 1.90], favoring the ABT group; however, this 
difference was not statistically significant. High heteroge-
neity was observed (Figure 4).
Meta-analyses results for safety
Table III summarizes the results concerning safety. 
Three studies provided data related to the SAE and SI 
for one year of treatment (Kremer et al., 2006; Jonsson; 
Kobelt; Smolen, 2008; Westhovens et al., 2009a). Data on 
death were available in four studies (Kremer et al., 2005; 
Kremer et al., 2006; Weinblatt et al., 2006; Westhovens 
et al., 2009a). Data on malignancies were extracted from 
four studies (Kremer et al., 2005; Kremer et al., 2006; 
Weinblatt et al., 2006; Westhovens et al., 2009a).
The RR values were not statistically significant for 
any of these items (p values of 0.19, 0.58, 0.82 and 0.98 
for SAE, SI, malignancies and deaths, respectively).
Only the SAE data had values of I² higher than 
25% (I²=39%), corresponding moderate heterogeneity. 
The study responsible for this heterogeneity was that of 
Weinblatt et al. (2006); the only difference between this 
study and the others was the possibility that the patients 
used other DMARD besides MTX.
Meta-analyses results for tolerability
The results concerning withdrawals due to AE, SAE 
and a lack of efficacy for ABT at a dose of 10 mg/kg within 
one year of treatment are summarized in Figure 5.
Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis 787
FIGURE 4 - Meta-analyses of HAQ variation (top) and HAQ improvement ≥ 0.3 (bottom). ABT – abatacept; MTX – methotrexate. 
IV – inverse variance; CI – confidence interval; SD – standard deviation.
TABLE III - Safety results
Outcome Studies Participants Statistical Method Effect Estimate
SAE 3 2435 Risk Ratio (IV, Random, 95% CI) 1.27 [0.76, 2.13]
SI 3 2435 Risk Ratio (IV, Random, 95% CI) 1.52 [0.81, 2.85]
Malignancies 4 2669 Risk Ratio (IV, Random, 95% CI) 0.93 [0.55, 1.57]
Deaths 4 2669 Risk Ratio (IV, Random, 95% CI) 0.56 [0.21, 1.47]
SAE: serious adverse events; SI: serious infections; IV: inverse variance; CI: confidence interval
There were no statistically significant differences 
between the intervention and control groups in any of the 
evaluated parameters, except in the meta-analysis of the 
proportion of patients who withdrew from treatment due to 
a lack of efficacy (RR of 0.29 [0.12, 0.71]). This parameter 
exhibited high heterogeneity (I²=64%), which could not be 
explained by methodological differences between the stud-
ies. The value of RR of the withdrawals due to AE within 
one year of treatment also exhibited high heterogeneity, 
although the RR value was not statistically significant.
DISCUSSION
DMARDs and anticytokines, such as adalimumab, 
etanercept or infliximab, are used worldwide to control the 
symptoms of RA, but in some patients, the results are not 
satisfactory (Bértolo et al., 2007; Russell, A. et al., 2009). 
Other biological agents have been developed to treat these 
refractory patients. Recent studies showed the effective-
ness of these agents, including ABT and rituximab (RTX), 
for the treatment of RA. The evidence obtained from clini-
cal trials is promising for the reduction of disease progres-
sion (Toussirot; Wendling, 2004; Smolen et al., 2007). The 
remission of the disease is more likely when ABT is used 
in the early stages of RA (Tang et al., 2008); in this study, 
only two trials (Moreland et al., 2002; Westhovens et al., 
2009a) included patients who were within less than three 
years of disease onset.
In this study, the ABT-treated patients showed better 
efficacy and tolerability, compared to the control group. 
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FIGURE 5 - Meta-analysis of withdrawals due to AE, SAE and a lack of efficacy (top, middle and bottom, respectively). ABT – 
abatacept; MTX – methotrexate. IV – inverse variance; CI – confidence interval.
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Better efficacy after one year of treatment was observed 
for all of the considered parameters (ACR20, ACR50, 
ACR70, DAS28≤3.2, DAS28≤2.6, mean HAQ variation, 
and the proportion of patients who had an improvement 
of 0.3 or more in the HAQ scale). The lower efficacy of 
the control group was also observed in the results of the 
meta-analyses of the withdrawals due lack of efficacy.
Our meta-analyses included the results of studies 
involving patients with early RA and patients with a long 
disease duration (with a mean duration of disease varying 
from 3.2 years to 12.2 years).
The safety data showed no differences between the 
groups with regard to SAE, serious infections, malignancy 
and deaths. The results of the analysis of withdrawals due 
to AE confirm this data, as there were no significant differ-
ences between the groups. Some of the common AE, SAE 
and serious infections cited in the studies were nausea, 
upper respiratory tract infection, headache, flu syndrome, 
rash and injection site reaction (Weinblatt et al., 2006; 
Westhovens et al., 2009b).
Other meta-analyses (Singh et al., 2009) have also 
shown benefits associated with the use of ABT instead of 
placebo (OR = 2.98 [1.79, 4.97]; RR = 1.03 (Zhang; Yu, 
1998)), including six studies with a total of 1712 patients 
that considered ACR50 as the effectiveness outcome. The 
same study presented a value of OR equal to 1.24 [0.88, 
1.76] (RR = 1.01 (Zhang; Yu, 1998)) for withdrawals due 
to AE; their meta-analysis included the same six studies 
but with a total of 1441 patients. Another meta-analysis 
presented similar results for the ACR50 (OR = 3.28 [2.44, 
4.41]; RR = 1.04 (Zhang; Yu, 1998)) but used the Mantel-
Haenszel method instead of the inverse variance method 
(Salliot et al.).
Only RCT were included in this study for the evalua-
tion of outcomes. However, long-term observational studies 
can provide a more realistic long-term estimation of the 
outcomes, especially the safety-related ones, reflecting the 
risks of ABT in the “real world”. RCT have insufficient 
numbers of patients and follow-up times to detect rare SAE.
This study included some important clinical out-
comes, such as the ACR and DAS28; however, other 
relevant outcomes could not be analyzed (such as radio-
graphic progression) because they were less often included 
in the reviewed RCT.
CONCLUSION
Our meta-analyses provided an updated comprehen-
sive picture of the clinical efficacy, safety and tolerability 
of ABT, which presented a higher efficacy for all consid-
ered parameters (ACR20, ACR50, ACR70, DAS28≤3.2, 
DAS28≤2.6, mean HAQ variation, and the proportion of 
patients who had an improvement of 0.3 or more in the 
HAQ scale) compared to placebo. However, there were 
no significant differences between the ABT and control 
groups in terms of safety and withdrawals due to AE and 
SAE. Furthermore, the ABT group presented fewer with-
drawals due to lack of efficacy.
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